{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:38:36Z","timestamp":1756895916130,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s12149-020-01554-8","type":"journal-article","created":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T10:03:09Z","timestamp":1609581789000},"page":"211-222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical value of PET\/CT with carbon-11 4DST in the evaluation of malignant and benign lung tumors"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2096-4611","authenticated-orcid":false,"given":"Ryuichi","family":"Nishii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneo","family":"Saga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junpei","family":"Kuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamasa","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Iizasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Shingyoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Itami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,2]]},"reference":[{"key":"1554_CR1","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ejrad.2009.03.051","volume":"70","author":"TD Poeppel","year":"2009","unstructured":"Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET\/CT for the staging and follow-up of patients with malignancies. Eur J Radiol. 2009;70:382\u201392. https:\/\/doi.org\/10.1016\/j.ejrad.2009.03.051.","journal-title":"Eur J Radiol"},{"key":"1554_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/j.semnuclmed.2007.01.001","volume":"37","author":"U Metser","year":"2007","unstructured":"Metser U, Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography\/computed tomography (PET\/CT): accumulated data from four years of experience with PET\/CT. Semin Nucl Med. 2007;37:206\u201322. https:\/\/doi.org\/10.1053\/j.semnuclmed.2007.01.001.","journal-title":"Semin Nucl Med"},{"key":"1554_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3348\/kjr.2006.7.1.57","volume":"7","author":"JM Chang","year":"2006","unstructured":"Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol. 2006;7:57\u201369.","journal-title":"Korean J Radiol"},{"key":"1554_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/BF02988521","volume":"17","author":"T Higashi","year":"2003","unstructured":"Higashi T, Saga T, Nakamoto Y, Ishimori T, Fujimoto K, Doi R, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)\u2014usefulness and limitations in \u201cclinical reality.\u201d Ann Nucl Med. 2003;17:261\u201379.","journal-title":"Ann Nucl Med"},{"key":"1554_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1148\/radiographics.19.1.g99ja0761","volume":"19","author":"PD Shreve","year":"1999","unstructured":"Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61\u201377. https:\/\/doi.org\/10.1148\/radiographics.19.1.g99ja0761 ((quiz 150\u20131)).","journal-title":"Radiographics"},{"key":"1554_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/RLU.0b013e3182173810","volume":"36","author":"M Hu","year":"2011","unstructured":"Hu M, Han A, Xing L, Yang W, Fu Z, Huang C, et al. Value of dual-time-point FDG PET\/CT for mediastinal nodal staging in non-small-cell lung cancer patients with lung comorbidity. Clin Nucl Med. 2011;36:429\u201333. https:\/\/doi.org\/10.1097\/RLU.0b013e3182173810.","journal-title":"Clin Nucl Med"},{"key":"1554_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.athoracsur.2011.02.052","volume":"92","author":"S Deppen","year":"2011","unstructured":"Deppen S, Putnam JB Jr, Andrade G, Speroff T, Nesbitt JC, Lambright ES, et al. Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease. Ann Thorac Surg. 2011;92:428\u201332. https:\/\/doi.org\/10.1016\/j.athoracsur.2011.02.052 ((discussion 33)).","journal-title":"Ann Thorac Surg"},{"key":"1554_CR8","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1007\/s00259-009-1155-4","volume":"36","author":"JW Lee","year":"2009","unstructured":"Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. 18F-FDG PET\/CT in mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic country: consideration of lymph node calcification and distribution pattern to improve specificity. Eur J Nucl Med Mol Imaging. 2009;36:1794\u2013802. https:\/\/doi.org\/10.1007\/s00259-009-1155-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1554_CR9","doi-asserted-by":"publisher","first-page":"5282698","DOI":"10.1155\/2020\/5282698","volume":"2020","author":"F Lococo","year":"2020","unstructured":"Lococo F, Muoio B, Chiappetta M, Nachira D, Petracca Ciavarella L, Margaritora S, et al. Diagnostic performance of PET or PET\/CT with different radiotracers in patients with suspicious lung cancer or pleural tumours according to published meta-analyses. Contrast Media Mol Imaging. 2020;2020:5282698. https:\/\/doi.org\/10.1155\/2020\/5282698.","journal-title":"Contrast Media Mol Imaging"},{"key":"1554_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s12149-018-1284-6","volume":"32","author":"K Mitamura","year":"2018","unstructured":"Mitamura K, Yamamoto Y, Norikane T, Hatakeyama T, Okada M, Nishiyama Y. Correlation of (18)F-FDG and (11)C-methionine uptake on PET\/CT with Ki-67 immunohistochemistry in newly diagnosed intracranial meningiomas. Ann Nucl Med. 2018;32:627\u201333. https:\/\/doi.org\/10.1007\/s12149-018-1284-6.","journal-title":"Ann Nucl Med"},{"key":"1554_CR11","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1007\/s00261-016-0987-1","volume":"42","author":"M Nakajo","year":"2017","unstructured":"Nakajo M, Kajiya Y, Tani A, Jinguji M, Nakajo M, Nihara T, et al. A pilot study of the diagnostic and prognostic values of FLT-PET\/CT for pancreatic cancer: comparison with FDG-PET\/CT. Abdom Radiol (NY). 2017;42:1210\u201321. https:\/\/doi.org\/10.1007\/s00261-016-0987-1.","journal-title":"Abdom Radiol (NY)"},{"key":"1554_CR12","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12149-012-0597-0","volume":"26","author":"T Yamane","year":"2012","unstructured":"Yamane T, Takaoka A, Kita M, Imai Y, Senda M. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma. Ann Nucl Med. 2012;26:478\u201384. https:\/\/doi.org\/10.1007\/s12149-012-0597-0.","journal-title":"Ann Nucl Med"},{"key":"1554_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ejrad.2009.12.022","volume":"73","author":"W Wadsak","year":"2010","unstructured":"Wadsak W, Mitterhauser M. Basics and principles of radiopharmaceuticals for PET\/CT. Eur J Radiol. 2010;73:461\u20139. https:\/\/doi.org\/10.1016\/j.ejrad.2009.12.022.","journal-title":"Eur J Radiol"},{"key":"1554_CR14","first-page":"1717","volume":"47","author":"J Toyohara","year":"2006","unstructured":"Toyohara J, Kumata K, Fukushi K, Irie T, Suzuki K. Evaluation of 4\u2032-[methyl-14C]thiothymidine for in vivo DNA synthesis imaging. J Nucl Med. 2006;47:1717\u201322.","journal-title":"J Nucl Med"},{"key":"1554_CR15","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s12149-018-1285-5","volume":"32","author":"Y Takami","year":"2018","unstructured":"Takami Y, Yamamoto Y, Ueno M, Chiba Y, Norikane T, Hatakeyama T, et al. Correlation of 4\u2032-[methyl-(11)C]-thiothymidine uptake with human equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in patients with newly diagnosed gliomas. Ann Nucl Med. 2018;32:634\u201341. https:\/\/doi.org\/10.1007\/s12149-018-1285-5.","journal-title":"Ann Nucl Med"},{"key":"1554_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13550-015-0085-3","volume":"5","author":"Y Toyota","year":"2015","unstructured":"Toyota Y, Miyake K, Kawai N, Hatakeyama T, Yamamoto Y, Toyohara J, et al. Comparison of 4\u2032-[methyl-(11)C]thiothymidine ((11)C-4DST) and 3\u2032-deoxy-3\u2032-[(18)F]fluorothymidine ((18)F-FLT) PET\/CT in human brain glioma imaging. EJNMMI Res. 2015;5:7. https:\/\/doi.org\/10.1186\/s13550-015-0085-3.","journal-title":"EJNMMI Res"},{"key":"1554_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12149-015-1035-x","volume":"30","author":"K Tanaka","year":"2015","unstructured":"Tanaka K, Yamamoto Y, Maeda Y, Yamamoto H, Kudomi N, Kawai N, et al. Correlation of 4\u2032-[methyl-(11)C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with (11)C-methionine uptake. Ann Nucl Med. 2015;30:89\u201396. https:\/\/doi.org\/10.1007\/s12149-015-1035-x.","journal-title":"Ann Nucl Med"},{"key":"1554_CR18","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2967\/jnumed.111.088435","volume":"52","author":"J Toyohara","year":"2011","unstructured":"Toyohara J, Nariai T, Sakata M, Oda K, Ishii K, Kawabe T, et al. Whole-body distribution and brain tumor imaging with (11)C-4DST: a pilot study. J Nucl Med. 2011;52:1322\u20138. https:\/\/doi.org\/10.2967\/jnumed.111.088435.","journal-title":"J Nucl Med"},{"key":"1554_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12149-016-1131-6","volume":"31","author":"H Hoshikawa","year":"2017","unstructured":"Hoshikawa H, Mori T, Maeda Y, Takahashi S, Ouchi Y, Yamamoto Y, et al. Influence of volumetric 4\u2032-[methyl-11C]-thiothymidine PET\/CT parameters for prediction of the clinical outcome of head and neck cancer patients. Ann Nucl Med. 2017;31:63\u201370. https:\/\/doi.org\/10.1007\/s12149-016-1131-6.","journal-title":"Ann Nucl Med"},{"key":"1554_CR20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/MNM.0000000000000241","volume":"36","author":"K Ito","year":"2015","unstructured":"Ito K, Yokoyama J, Miyata Y, Toyohara J, Okasaki M, Minamimoto R, et al. Volumetric comparison of positron emission tomography\/computed tomography using 4\u2032-[methyl-(1)(1)C]-thiothymidine with 2-deoxy-2-(1)(8)F-fluoro-d-glucose in patients with advanced head and neck squamous cell carcinoma. Nucl Med Commun. 2015;36:219\u201325. https:\/\/doi.org\/10.1097\/MNM.0000000000000241.","journal-title":"Nucl Med Commun"},{"key":"1554_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12149-014-0931-9","volume":"29","author":"M Okasaki","year":"2015","unstructured":"Okasaki M, Kubota K, Minamimoto R, Miyata Y, Morooka M, Ito K, et al. Comparison of (11)C-4\u2032-thiothymidine, (11)C-methionine, and (18)F-FDG PET\/CT for the detection of active lesions of multiple myeloma. Ann Nucl Med. 2015;29:224\u201332. https:\/\/doi.org\/10.1007\/s12149-014-0931-9.","journal-title":"Ann Nucl Med"},{"key":"1554_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00261-015-0601-y","volume":"41","author":"R Minamimoto","year":"2016","unstructured":"Minamimoto R, Nakaigawa N, Nagashima Y, Toyohara J, Ueno D, Namura K, et al. Comparison of 11C-4DST and 18F-FDG PET\/CT imaging for advanced renal cell carcinoma: preliminary study. Abdom Radiol (NY). 2016;41:521\u201330. https:\/\/doi.org\/10.1007\/s00261-015-0601-y.","journal-title":"Abdom Radiol (NY)"},{"key":"1554_CR23","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s12149-019-01393-2","volume":"33","author":"Y Fukuda","year":"2019","unstructured":"Fukuda Y, Yamamoto Y, Mitamura K, Ishikawa R, Asano E, Toyohara J, et al. 4\u2032-[Methyl-(11)C]-thiothymidine as a proliferation imaging tracer for detection of colorectal cancer: comparison with (18)F-FDG. Ann Nucl Med. 2019;33:822\u20137. https:\/\/doi.org\/10.1007\/s12149-019-01393-2.","journal-title":"Ann Nucl Med"},{"key":"1554_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13550-019-0478-9","volume":"9","author":"M Hotta","year":"2019","unstructured":"Hotta M, Minamimoto R, Yamada K, Nohara K, Soma D, Nakajima K, et al. Efficacy of 4\u2032-[methyl-11C] thiothymidine PET\/CT before and after neoadjuvant therapy for predicting therapeutic responses in patients with esophageal cancer: a pilot study. EJNMMI Res. 2019;9:10. https:\/\/doi.org\/10.1186\/s13550-019-0478-9.","journal-title":"EJNMMI Res"},{"key":"1554_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13550-019-0472-2","volume":"9","author":"R Minamimoto","year":"2019","unstructured":"Minamimoto R, Takeda Y, Hotta M, Toyohara J, Nakajima K, Naka G, et al. (18)F-FDG and (11)C-4DST PET\/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study. EJNMMI Res. 2019;9:4. https:\/\/doi.org\/10.1186\/s13550-019-0472-2.","journal-title":"EJNMMI Res"},{"key":"1554_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2191-219X-4-10","volume":"4","author":"R Minamimoto","year":"2014","unstructured":"Minamimoto R, Toyohara J, Ito H, Seike A, Miyata Y, Morooka M, et al. A pilot study of 4\u2032-[methyl-11C]-thiothymidine PET\/CT for detection of regional lymph node metastasis in non-small cell lung cancer. EJNMMI Res. 2014;4:10. https:\/\/doi.org\/10.1186\/2191-219X-4-10.","journal-title":"EJNMMI Res"},{"key":"1554_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2967\/jnumed.111.095539","volume":"53","author":"R Minamimoto","year":"2012","unstructured":"Minamimoto R, Toyohara J, Seike A, Ito H, Endo H, Morooka M, et al. 4\u2032-[Methyl-11C]-thiothymidine PET\/CT for proliferation imaging in non-small cell lung cancer. J Nucl Med. 2012;53:199\u2013206. https:\/\/doi.org\/10.2967\/jnumed.111.095539.","journal-title":"J Nucl Med"},{"key":"1554_CR28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.nucmedbio.2012.10.008","volume":"40","author":"J Toyohara","year":"2013","unstructured":"Toyohara J, Sakata M, Oda K, Ishii K, Ishiwata K. Longitudinal observation of [11C]4DST uptake in turpentine-induced inflammatory tissue. Nucl Med Biol. 2013;40:240\u20134. https:\/\/doi.org\/10.1016\/j.nucmedbio.2012.10.008.","journal-title":"Nucl Med Biol"},{"key":"1554_CR29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2967\/jnumed.111.098426","volume":"53","author":"J Toyohara","year":"2012","unstructured":"Toyohara J, Elsinga PH, Ishiwata K, Sijbesma JW, Dierckx RA, van Waarde A. Evaluation of 4\u2032-[methyl-11C]thiothymidine in a rodent tumor and inflammation model. J Nucl Med. 2012;53:488\u201394. https:\/\/doi.org\/10.2967\/jnumed.111.098426.","journal-title":"J Nucl Med"},{"key":"1554_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-020-02196-z","author":"R Minamimoto","year":"2020","unstructured":"Minamimoto R, Nakajima K, Okazaki O. Proliferation PET tracer (11)C-4DST PET\/CT depicts hibernating myocardium. J Nucl Cardiol. 2020. https:\/\/doi.org\/10.1007\/s12350-020-02196-z.","journal-title":"J Nucl Cardiol"},{"key":"1554_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.nucmedbio.2007.10.001","volume":"35","author":"J Toyohara","year":"2008","unstructured":"Toyohara J, Okada M, Toramatsu C, Suzuki K, Irie T. Feasibility studies of 4\u2032-[methyl-(11)C]thiothymidine as a tumor proliferation imaging agent in mice. Nucl Med Biol. 2008;35:67\u201374. https:\/\/doi.org\/10.1016\/j.nucmedbio.2007.10.001.","journal-title":"Nucl Med Biol"},{"key":"1554_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/BF02985960","volume":"18","author":"T Ishimori","year":"2004","unstructured":"Ishimori T, Saga T, Nagata Y, Nakamoto Y, Higashi T, Mamede M, et al. 18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med. 2004;18:669\u201374.","journal-title":"Ann Nucl Med"},{"key":"1554_CR33","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.jpurol.2014.02.006","volume":"10","author":"FA Ferrer","year":"2014","unstructured":"Ferrer FA, Herbst KW, Fernandez CV, Khanna G, Dome JS, Naranjo A, et al. Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: implications for central venous catheter placement. J Pediatr Urol. 2014;10:969\u201373. https:\/\/doi.org\/10.1016\/j.jpurol.2014.02.006.","journal-title":"J Pediatr Urol"},{"key":"1554_CR34","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1038\/s41416-020-0815-9","volume":"122","author":"H Mukai","year":"2020","unstructured":"Mukai H, Yamaguchi T, Takahashi M, Hozumi Y, Fujisawa T, Ohsumi S, et al. Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised phase 2 study. Br J Cancer. 2020;122:1747\u201353. https:\/\/doi.org\/10.1038\/s41416-020-0815-9.","journal-title":"Br J Cancer"},{"key":"1554_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00259-004-1713-8","volume":"32","author":"H Sun","year":"2005","unstructured":"Sun H, Sloan A, Mangner TJ, Vaishampayan U, Muzik O, Collins JM, et al. Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging. 2005;32:15\u201322. https:\/\/doi.org\/10.1007\/s00259-004-1713-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1554_CR36","first-page":"974","volume":"35","author":"T Vander Borght","year":"1994","unstructured":"Vander Borght T, Pauwels S, Lambotte L, Labar D, De Maeght S, Stroobandt G, et al. Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med. 1994;35:974\u201382.","journal-title":"J Nucl Med"},{"key":"1554_CR37","first-page":"337","volume":"31","author":"AF Shields","year":"1990","unstructured":"Shields AF, Lim K, Grierson J, Link J, Krohn KA. Utilization of labeled thymidine in DNA synthesis: studies for PET. J Nucl Med. 1990;31:337\u201342.","journal-title":"J Nucl Med"},{"key":"1554_CR38","first-page":"1633","volume":"29","author":"P Martiat","year":"1988","unstructured":"Martiat P, Ferrant A, Labar D, Cogneau M, Bol A, Michel C, et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin\u2019s lymphoma using positron emission tomography. J Nucl Med. 1988;29:1633\u20137.","journal-title":"J Nucl Med"},{"key":"1554_CR39","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1073\/pnas.69.4.988","volume":"69","author":"D Christman","year":"1972","unstructured":"Christman D, Crawford EJ, Friedkin M, Wolf AP. Detection of DNA synthesis in intact organisms with positron-emitting (methyl-11 C)thymidine. Proc Natl Acad Sci USA. 1972;69:988\u201392. https:\/\/doi.org\/10.1073\/pnas.69.4.988.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1554_CR40","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1158\/1078-0432.Ccr-05-2720","volume":"12","author":"S Apisarnthanarax","year":"2006","unstructured":"Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, et al. Early detection of chemoradioresponse in esophageal carcinoma by 3\u2032-deoxy-3\u2032-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006;12:4590\u20137. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-05-2720.","journal-title":"Clin Cancer Res"},{"key":"1554_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0720-048x(96)01114-x","volume":"24","author":"E Lifrange","year":"1997","unstructured":"Lifrange E, Kridelka F, Colin C. Stereotaxic needle-core biopsy and fine-needle aspiration biopsy in the diagnosis of nonpalpable breast lesions: controversies and future prospects. Eur J Radiol. 1997;24:39\u201347. https:\/\/doi.org\/10.1016\/s0720-048x(96)01114-x.","journal-title":"Eur J Radiol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-020-01554-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-020-01554-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-020-01554-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T21:46:18Z","timestamp":1613771178000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-020-01554-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1554"],"URL":"https:\/\/doi.org\/10.1007\/s12149-020-01554-8","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"type":"print","value":"0914-7187"},{"type":"electronic","value":"1864-6433"}],"subject":[],"published":{"date-parts":[[2021,1,2]]},"assertion":[{"value":"7 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have no potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This prospective clinical study registered in UMIN Clinical Trials Registry (#UMIN000011790) was approved by the Institutional Review Board (#12-027). All enrolled patients received explanations, and then they provided written informed consent regarding this clinical study. Our study was conducted in accordance with the principles outlined in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}